The lower-than-expected sales guidance for Lumryz due to patient attrition is a negative indicator for Avadel Pharmaceuticals. Although the company is taking steps to address these issues, the immediate impact on sales and investor sentiment is likely negative. The legal updates reducing risk are positive, but the loss in the idiopathic hypersomnia market adds to the challenges.